Sana Biotechnology (NASDAQ:SANA) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Sana Biotechnology (NASDAQ:SANA) posted its quarterly earnings data on Thursday. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.03, Zacks reports.

Sana Biotechnology Stock Performance

Shares of NASDAQ:SANA traded down $0.03 during trading on Thursday, hitting $4.05. The company’s stock had a trading volume of 3,251,435 shares, compared to its average volume of 6,835,853. Sana Biotechnology has a fifty-two week low of $1.26 and a fifty-two week high of $7.30. The stock’s 50-day moving average price is $4.02 and its two-hundred day moving average price is $3.32. The company has a market capitalization of $963.13 million, a PE ratio of -3.82 and a beta of 1.94.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. AQR Capital Management LLC increased its holdings in Sana Biotechnology by 136.7% in the second quarter. AQR Capital Management LLC now owns 1,356,363 shares of the company’s stock valued at $3,703,000 after buying an additional 783,217 shares during the last quarter. Corient Private Wealth LLC increased its holdings in Sana Biotechnology by 264.7% in the second quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock valued at $3,101,000 after buying an additional 824,505 shares during the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in Sana Biotechnology in the second quarter valued at about $1,916,000. Woodline Partners LP increased its holdings in Sana Biotechnology by 13.1% in the first quarter. Woodline Partners LP now owns 780,656 shares of the company’s stock valued at $1,312,000 after buying an additional 90,515 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in Sana Biotechnology by 64.8% in the second quarter. Invesco Ltd. now owns 272,981 shares of the company’s stock valued at $745,000 after buying an additional 107,335 shares during the last quarter. Institutional investors and hedge funds own 88.23% of the company’s stock.

Wall Street Analyst Weigh In

SANA has been the topic of several research reports. Citizens Jmp increased their target price on Sana Biotechnology from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research report on Thursday, October 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sana Biotechnology in a research report on Wednesday, October 8th. JMP Securities set a $8.00 target price on Sana Biotechnology in a research report on Thursday, October 30th. Citigroup reaffirmed an “outperform” rating on shares of Sana Biotechnology in a research report on Thursday, October 30th. Finally, Wedbush initiated coverage on Sana Biotechnology in a research report on Wednesday, September 24th. They issued an “outperform” rating and a $5.00 target price on the stock. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Sana Biotechnology has a consensus rating of “Moderate Buy” and an average target price of $8.50.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.